rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

CervoMed Inc.

CRVO · Nasdaq

Health CareBiotechnologyNot moving yet

CRVO stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 29.9% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$6.7M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
36 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$5.8MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months15
Sale orders, 12 months0
Buyers · sellers5 · 0
WhoDidSharesTraded
Joshua S. BogerDirector, 10% ownerbought955,414at $3.1411 Jun 2026filed 15 Jun 2026
Joshua S. BogerDirector, 10% ownerbought955,41411 Jun 2026filed 15 Jun 2026
Joshua S. BogerDirector, 10% ownerbought955,41411 Jun 2026filed 15 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders36+0 on the quarter
New · exited6 · 6
Reported value$5.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Woodline Partners LPnew · filed 14 Aug 2026688,987$2.1M+688,987
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 2026316,202$980K00.0%
SABBY MANAGEMENT, LLCnew · filed 14 Aug 2026248,880$772K+248,880
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202666,923$208K-7,448−10.0%
BlackRock, Inc.added · filed 7 Aug 202653,845$167K+2,185+4.2%
Byrne Asset Management LLCadded · filed 7 Jul 202651,250$159K+36,550+248.6%
CITIZENS FINANCIAL GROUP INCunchanged · filed 7 Aug 202637,477$116K00.0%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202636,151$112K00.0%
JANE STREET GROUP, LLCadded · filed 14 Aug 202632,231$100K+13,985+76.6%
THOMPSON DAVIS & CO., INC.added · filed 29 Jul 202629,750$92K+19,750+197.5%
30 Sep 2023 – 30 Jun 2026
112743Sep 23Jun 24Mar 25Sep 25Jun 26

Everyone who traded it

Joshua S. Boger Company insiderDirector, 10% owner · last 11 Jun 20261 · 1
David Quigley Company insiderDirector · last 8 Jun 20260 · 0
Frank Zavrl Company insiderDirector · last 8 Jun 20260 · 0
Jane H. Hollingsworth Company insiderDirector · last 8 Jun 20261 · 0
Jeffrey Poulton V Company insiderDirector · last 8 Jun 20260 · 0
John J. Alam Company insiderCEO & President · last 8 Jun 20264 · 0
Marwan Sabbagh Company insiderDirector · last 8 Jun 20260 · 0
Sylvie Gregoire Company insiderDirector, 10% owner · last 8 Jun 20264 · 0
Kelly Blackburn Company insiderEVP, Clinical Development · last 11 Feb 20260 · 0
Mark De Rosch Company insiderEVP, RA and GA and PgM · last 11 Feb 20260 · 0
Matthew Winton Company insiderChief Commercial and Business · last 11 Feb 20263 · 0
William Robert Elder Company insiderCFO, GC & Secretary · last 11 Feb 20267 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-706%
Return on capital employedFY 2025 · to 31 Dec 2025-155%
Share count trendFY 2025 · to 12 Mar 20260.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$8.2M

Analyst forecasts

No analyst forecasts yet.